Effects of the COVID-19 booster vaccine on glycemia and insulin resistance in people with type 1 diabetes: A prospective pilot study
Authors' conclusion
These results suggest that adults with type 1 diabetes may experience transient mild glycemic elevations after receiving a COVID-19 booster vaccination. Studies examining the effects of other vaccines are warranted.
Study context
- Population
- Adults with T1D receiving a COVID-19 booster vaccine (38% Moderna, 62% Pfizer-BioNTech)enrolled
- Participants
- 21 adults
- Exposure
- Post-vaccination vs pre-vaccination baseline
- Outcome
- Changes in glycemic control and insulin usage around a COVID-19 booster vaccine
Methodological detailspilot, blinded CGM, Blinded Dexcom G6 Pro CGM worn for 10 days
- Pilot
- Blinded CGM
- Blinded Dexcom G6 Pro CGM worn for 10 days
Main finding
As reported in the abstract
Mean glucose
Day 2 vs Baseline: P = 0.04 · Day 3 vs Baseline: P = 0.02
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Insulin resistance · Day 2Day 2 vs Baseline · increased | P = 0.03 |
Outcome metrics by booster vaccine manufacturer
- No differences in outcome metrics between booster vaccine manufacturers
Original publication
Effects of the COVID-19 booster vaccine on glycemia and insulin resistance in people with type 1 diabetes: A prospective pilot study. Diabetes Res Clin Pract. Published 9 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →